2020 ESMO/EURACAN《肾上腺皮质癌和恶性嗜铬细胞瘤:诊断、治疗和随访的临床实践指南》解读

Interpretation of the adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up

肾上腺皮质癌和恶性嗜铬细胞瘤因发病率极低而归属为罕见病, 但因其恶性程度较高, 严重威胁人类的健康及预期寿命。目前我国仅有关于肾上腺皮质癌的专家共识, 尚无多学科专家制定的中国指南, 因此研学相关指南对治疗该类疾病具有重要的指导意义。欧洲肿瘤内科学会和欧洲罕见成人实体癌症参考网络基于新的临床证据首次合作出台了《肾上腺皮质癌和恶性嗜铬细胞瘤:诊断、治疗和随访的临床实践指南》, 本文结合最新的研究进展对该疾病的诊断、治疗、管理及随访进行全面的解读。

Adrenocortical carcinoma and malignant pheochromocytoma are classified as rare diseases because of their low incidence,but seriously threaten human health and life expectancy because of their high degree of malignancy.At present,there is only a consensus of experts on adrenal cortical cancer in China,and there is no Chinese guideline formulated by multidisciplinary experts.Therefore,the study of relevant guidelines can provide important guiding significance for the treatment of these diseases.The European Society of Physicians of Oncology and the European Rare Adult Solid Cancer Reference Network have jointly published the adrenocortical carcinomas and malignant phaeochromocytomas:ESMO-EURACAN clinical practice guidelines for diagnosis,treatment,and follow-up,based on new clinical evidence.This article will comprehensively interpret the diagnosis,staging evaluation,treatment management,and follow-up of this disease according to the latest research progress.